REG - Haleon PLC - Total Voting Rights and Capital

HALEONAnnouncement

02/04/2024 09:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240402:nRSB9316Ia&default-theme=true

RNS Number : 9316I  Haleon PLC  02 April 2024

 

 

Haleon plc: Total Voting Rights and Capital

 

2 April 2024: As at 31 March 2024 the total number of shares issued by Haleon
plc ("Haleon" or the "Company") with rights to vote is 9,132,301,104 ordinary
shares of £0.01 each. There are no ordinary shares held in Treasury.

 

The figure of 9,132,301,104 may be used by shareholders (and others with
notification obligations) as the denominator for the calculation by which they
will determine if they are required to notify their interest in, or a change
to their interest in, the Company under the FCA's Disclosure Guidance and
Transparency Rules.

 

Notifiable interests in Haleon may be sent to: company.secretary@haleon.com
(mailto:company.secretary@haleon.com)

 

Amanda Mellor

Company Secretary

 

 

About Haleon

Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose
to deliver better everyday health with humanity. Haleon's product portfolio
spans five major categories - Oral Health, Pain Relief, Respiratory Health,
Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its
long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu,
Otrivin, Polident, parodontax and Centrum - are built on trusted science,
innovation and deep human understanding.

 

For more information, please visit www.haleon.com (http://www.haleon.com/)
.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRUURWRSNUSRRR